Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows (unaudited)

v3.22.2.2
Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Cash flows from operating activities:    
Net loss $ (18,850) $ (12,186)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 607 523
Stock-based compensation 1,392 994
Non-cash interest expense 382 346
Non-cash advertising expense 200
Non-cash portion of loss on debt extinguishment 1,087 161
Forgiveness of PPP loan (2,180)
Non-cash lease expense 572
Provision for bad debt 15
Deferred rent 355
Changes in operating assets and liabilities:    
Accounts receivable 2,109 (2,849)
Prepaid expenses, deposits and other assets 101 392
Accounts payable (111) 942
Accrued expenses and other liabilities 632 229
Deferred revenue 150 269
Lease liability (636)
Customer deposits (37) (306)
Net cash used in operating activities (12,387) (13,310)
Cash flows from investing activities:    
Purchase of property and equipment (816) (423)
Net cash used in investing activities (816) (423)
Cash flows from financing activities:    
Proceeds from loan payable 15,000 15,000
Repayment of loan payable (16,125) (12,966)
Payment to unaccredited investors of Augmedix Operating Corporation (22)
Payment of financing costs (142) (232)
Payment of offering costs in relation to equity issuance (16)
Proceeds from exercise of common stock warrants 4
Proceeds from exercise of stock options 23 113
Net cash (used in) provided by financing activities (1,244) 1,881
Effect of exchange rate changes on cash and restricted cash (143) (3)
Net decrease in cash and restricted cash (14,590) (11,855)
Cash, cash equivalents and restricted cash at beginning of period 41,587 22,973
Cash, cash equivalents and restricted cash at end of period 26,997 11,118
Supplemental disclosure of cash flow information:    
Cash paid during the period for interest 815 1,290
Cash paid during the period for income taxes 13
Supplemental schedule of non-cash investing and financing activities:    
Deferred offering costs in accounts payable and accrued expenses 192
Fair value of warrants issued in connection with loan 72 395
Fair value of common stock issued to service provider 600
Property, and equipment in accounts payable $ 184 $ 83